Adverse events potentially associated with acetylcholinesterase inhibition, a known effect of gepotidacin based on in vitro competitive and reversible inhibition of the enzyme at clinically relevant concentrations [28], include dizziness, hyperhidrosis, and headache and were experienced by ≤6 participants in either treatment group. This evidence concerns the gene ACHE and Hyperhidrosis.